Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,846
  • Shares Outstanding, K 33,379
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,920 K
  • EBIT $ -58 M
  • EBITDA $ -57 M
  • 60-Month Beta 2.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.40
  • Most Recent Earnings $-0.36 on 03/10/26
  • Next Earnings Date 05/14/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 403.49% (-284.44%)
  • Historical Volatility 73.73%
  • IV Percentile 82%
  • IV Rank 27.02%
  • IV High 1,135.22% on 03/17/26
  • IV Low 132.62% on 10/13/25
  • Expected Move (DTE 10) 1.6150 (228.75%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 1,587
  • Open Int (30-Day) 2,998
  • Expected Range 0.0000 to 2.3210

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 3
  • High Estimate $-0.20
  • Low Estimate $-0.36
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) -3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5655 +24.85%
on 03/30/26
0.8350 -15.45%
on 03/10/26
-0.0144 (-2.00%)
since 03/06/26
3-Month
0.5655 +24.85%
on 03/30/26
1.1400 -38.07%
on 01/08/26
-0.4040 (-36.40%)
since 01/07/26
52-Week
0.5655 +24.85%
on 03/30/26
5.7500 -87.72%
on 06/27/25
-0.6840 (-49.21%)
since 04/07/25

Most Recent Stories

More News
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.7060 (-1.18%)
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.7060 (-1.18%)
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts; Received written FDA Type C meeting minutes;...

SKYE : 0.7060 (-1.18%)
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and...

SKYE : 0.7060 (-1.18%)
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab...

SKYE : 0.7060 (-1.18%)
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.7060 (-1.18%)
Skye Bioscience to Present Poster at Keystone Obesity Conference

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.7060 (-1.18%)
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

LOS ANGELES , Jan. 19, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations...

SKYE : 0.7060 (-1.18%)
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Jan. 19, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience,...

SKYE : 0.7060 (-1.18%)
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

NEW YORK , Jan. 16, 2026 /PRNewswire/ -- 

SKYE : 0.7060 (-1.18%)

Business Summary

Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.

See More

Key Turning Points

3rd Resistance Point 0.7787
2nd Resistance Point 0.7539
1st Resistance Point 0.7299
Last Price 0.7060
1st Support Level 0.6811
2nd Support Level 0.6563
3rd Support Level 0.6323

See More

52-Week High 5.7500
Fibonacci 61.8% 3.7695
Fibonacci 50% 3.1578
Fibonacci 38.2% 2.5460
Last Price 0.7060
52-Week Low 0.5655

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.